發表在Diabetes Care的一項研究: 對象為前驅期糖尿病(prediabetes)和/或代謝綜合征(and/or metabolic syndrome (MetS))人群,BMI在27~25 kg/m2之間。受試者接受為期108周的苯丁胺和托吡酯緩釋劑治療,同時進行生活方式調整。結果顯示,這種治療方案可顯著降低體重,並降低發展為2型糖尿病的風險。
CONCLUSIONS PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
原文鏈接:
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
注釋:
苯丁胺 = phentermine
托吡酯緩釋劑 = topiramate extended release (PHEN/TPM ER)
Fasting Plasma Glucose (FPG) = 空腹血糖
OGTT = oral glucose tolerance test (口服葡萄糖耐量試驗)
HbA1c = Hemoglobin A1c (糖化血紅蛋白)